This Indefinite Delivery Contract (IDC) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Specgx LLC, doing business as Mallinckrodt Pharmaceuticals, a foreign-owned, for-profit pharmaceutical manufacturer. The $1.4 million contract is for the supply of Atropine/Diphenoxylate HCL Tablets to the VA, Department of Defense, Bureau of Prisons, and Indian Health Service. The period of performance is one year from May 27, 2023, with four one-year option periods, for a total possible duration of five years.
The contract was awarded without the use of any set-aside designations, reflecting the specialized nature of the pharmaceutical products provided by Specgx. As a supplier of controlled substances and other products used in pain management and substance abuse treatment, Specgx leverages its expertise in developing, manufacturing, and distributing these specialized pharmaceutical items to support various federal healthcare programs and research initiatives. This award represents one component of Specgx's broader portfolio of federal contract IDVs, including a $107.6 million Federal Supply Schedule contract with the VA and a $28.2 million single-award IDC for the supply of buprenorphine hydrochloride/naloxone hydrochloride sublingual tablets.
Generated 1/31/25, 9:04 AM